MingMed Biotech Joins Queue of Revenue-less Drug Startups Seeking IPO Cash
It has seven drugs under development but none on the market yet. But one thing MingMed Biotech has plenty of is losses Key Takeaways: With no drug revenues and growing…
RELATED ARTICLES
-
Cancer drug maker Genfleet joins Hong Kong IPO influx
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- As Covid drug cash dwindles, Vigonvita targets new remedies
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
